Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Strong Trading Volume – Should You Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares saw unusually-strong trading volume on Thursday . Approximately 625 shares traded hands during trading, an increase of 79% from the previous session’s volume of 350 shares.The stock last traded at $16.00 and had previously closed at $16.70.

Ono Pharmaceutical Stock Performance

The stock has a market cap of $7.52 billion, a price-to-earnings ratio of 17.98 and a beta of 0.23. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The company’s 50 day simple moving average is $15.21 and its two-hundred day simple moving average is $13.08.

Ono Pharmaceutical (OTCMKTS:OPHLF) last issued its earnings results on Monday, February 2nd. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.11. Ono Pharmaceutical had a net margin of 12.29% and a return on equity of 7.76%. The company had revenue of $892.70 million during the quarter, compared to analyst estimates of $727.58 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.